Delivery Order SPE2DB22D1103-SPE2DB25FTSL2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $77,016.20 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injectors, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $13,729.56 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injectors. The contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. The delivery order is set to be completed by July 31, 2025, and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within a...
- The Defense Logistics Agency awarded a delivery order valued at $19,689.77 to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with a completion deadline of August 6, 2025. This competitive, firm fixed-price delivery order was issued without a set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award represents a continuation of the company's critical role as a...
- The Defense Logistics Agency awarded a delivery order valued at $7,887.13 to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml SureClick auto-injectors, with an ultimate completion date of July 28, 2025. This non-competitive delivery order represents a firm fixed-price transaction issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $13,844.92 delivery order to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This non-set-aside, competitively awarded contract utilized firm fixed pricing and was completed on July 24, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of the company's established role as a critical pharmaceutical supplier to the...
- The Defense Logistics Agency awarded a delivery order valued at $6,931.75 to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with an ultimate completion date of July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical supply transaction supporting federal medical...
- The Defense Logistics Agency awarded a delivery order valued at approximately $15,000 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injectors, with an ultimate completion date of July 31, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal medical procurement vendor for...
- The Defense Logistics Agency awarded a $35,063.69 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with an ultimate completion date of July 24, 2025. This is a firm fixed-price delivery order issued under a competitive process with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving critical federal medical procurement needs, particularly for military and...
- The Defense Logistics Agency awarded a delivery order valued at $42,776.04 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injectors. The contract, awarded on July 24, 2025, with an ultimate completion date of July 25, 2025, represents a firm fixed-price procurement with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,183.90 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FTSL2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,658.08 to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with an ultimate completion date of July 23, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's critical role as a federal medical supplier, particularly within the military healthcare supply chain. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical devices. The current award for Enbrel, a TNF inhibitor used in rheumatologic disease treatment, exemplifies the company's ongoing provision of specialized pharmaceutical commodities to Defense Health Agency and related federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.7k | 7/22/25 |